171 related articles for article (PubMed ID: 28802891)
41. Monoclonal B-cell lymphocytosis in the bone marrow: revisiting the criteria for chronic lymphocytic leukemia/small lymphocytic lymphoma.
Ryder CB; Oduro KA; Moore EM
Hum Pathol; 2022 Jul; 125():108-116. PubMed ID: 35472399
[TBL] [Abstract][Full Text] [Related]
42. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.
Tsimberidou AM; O'Brien S; Kantarjian HM; Koller C; Hagemeister FB; Fayad L; Lerner S; Bueso-Ramos CE; Keating MJ
Cancer; 2006 Sep; 107(6):1294-302. PubMed ID: 16902984
[TBL] [Abstract][Full Text] [Related]
43. Racial differences in three major NHL subtypes: descriptive epidemiology.
Li Y; Wang Y; Wang Z; Yi D; Ma S
Cancer Epidemiol; 2015 Feb; 39(1):8-13. PubMed ID: 25560974
[TBL] [Abstract][Full Text] [Related]
44. Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada.
Huang SJ; Chan J; Bruyère H; Allan LL; Gerrie AS; Toze CL
Leuk Res; 2019 Sep; 84():106193. PubMed ID: 31325731
[TBL] [Abstract][Full Text] [Related]
45. Dietary factors and risk of chronic lymphocytic leukemia and small lymphocytic lymphoma: a pooled analysis of two prospective studies.
Tsai HT; Cross AJ; Graubard BI; Oken M; Schatzkin A; Caporaso NE
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2680-4. PubMed ID: 20929883
[TBL] [Abstract][Full Text] [Related]
46. Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
Shustik C; Bence-Bruckler I; Delage R; Owen CJ; Toze CL; Coutre S
Ann Hematol; 2017 Jul; 96(7):1185-1196. PubMed ID: 28389687
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
Jones J; Mato A; Coutre S; Byrd JC; Furman RR; Hillmen P; Osterborg A; Tam C; Stilgenbauer S; Wierda WG; Heerema NA; Eckert K; Clow F; Zhou C; Chu AD; James DF; O'Brien SM
Br J Haematol; 2018 Aug; 182(4):504-512. PubMed ID: 29873072
[TBL] [Abstract][Full Text] [Related]
48. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
49. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
International CLL-IPI working group
Lancet Oncol; 2016 Jun; 17(6):779-790. PubMed ID: 27185642
[TBL] [Abstract][Full Text] [Related]
50. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Litchy S; Barton JH; Houston GA; Hermann RC; Bradof JE; Greco FA;
J Clin Oncol; 2003 May; 21(9):1746-51. PubMed ID: 12721250
[TBL] [Abstract][Full Text] [Related]
51. MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Ito M; Iida S; Inagaki H; Tsuboi K; Komatsu H; Yamaguchi M; Nakamura N; Suzuki R; Seto M; Nakamura S; Morishima Y; Ueda R
Jpn J Cancer Res; 2002 Jun; 93(6):685-94. PubMed ID: 12079517
[TBL] [Abstract][Full Text] [Related]
52. The pathological features of leukemic cells infiltrating the renal interstitium in chronic lymphocytic leukemia/small lymphocytic lymphoma from a large single Chinese center.
Wang H; Yu X; Zhang X; Wang S; Zhao M
Diagn Pathol; 2021 Jul; 16(1):59. PubMed ID: 34218814
[TBL] [Abstract][Full Text] [Related]
53. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center.
Tsimberidou AM; Wen S; O'Brien S; McLaughlin P; Wierda WG; Ferrajoli A; Faderl S; Manning J; Lerner S; Mai CV; Rodriguez AM; Hess M; Do KA; Freireich EJ; Kantarjian HM; Medeiros LJ; Keating MJ
J Clin Oncol; 2007 Oct; 25(29):4648-56. PubMed ID: 17925562
[TBL] [Abstract][Full Text] [Related]
54. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
[TBL] [Abstract][Full Text] [Related]
55. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Kyasa MJ; Parrish RS; Schichman SA; Zent CS
Am J Hematol; 2003 Sep; 74(1):1-8. PubMed ID: 12949883
[TBL] [Abstract][Full Text] [Related]
56. Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.
Song Y; Zhou K; Yang S; Hu J; Zou D; Gao S; Pan L; Wang T; Yang H; Zhang H; Zhou D; Ji J; Xu W; Feng R; Jin J; Lv F; Huang H; Fan X; Xu S; Zhu J
Invest New Drugs; 2023 Aug; 41(4):606-616. PubMed ID: 37420136
[TBL] [Abstract][Full Text] [Related]
57. Trends of incidence, mortality and survival for chronic lymphocytic leukaemia / small lymphocytic lymphoma in Switzerland between 1997 and 2016: a population-based study.
Andres M; Feller A; Arndt V; The Nicer Working Group
Swiss Med Wkly; 2021 Mar; 151():w20463. PubMed ID: 33793959
[TBL] [Abstract][Full Text] [Related]
58. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
Chang JE; Havighurst T; Kim K; Eickhoff J; Traynor AM; Kirby-Slimp R; Volk LM; Werndli J; Go RS; Weiss M; Blank J; Kahl BS
Br J Haematol; 2016 Apr; 173(2):283-91. PubMed ID: 26913697
[TBL] [Abstract][Full Text] [Related]
59. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
[TBL] [Abstract][Full Text] [Related]
60. Richter syndrome: A rare complication of chronic lymphocytic leukemia or small lymphocytic lymphoma.
Wąsik-Szczepanek E; Szymczyk A; Szczepanek D; Wszoła-Kleinrok J; Chocholska S; Pluta A; Hus M
Adv Clin Exp Med; 2018 Dec; 27(12):1683-1689. PubMed ID: 30156387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
